Du et al. [64] developed pathway-specific signatures in pre-treatment (PASS-PRE) and on-treatment (PASS-ON) tumor specimens based on transcriptomic data and clinical information from a large dataset of metastatic melanoma patients treated with anti-PD1. This evidence concerns the gene PDCD1 and neoplasm.